Pseudomonas aeruginosa (Pa) antibiotic resistance (AR): Comparison in adults and children with cystic fibrosis (CF)

D. Smith, T. Kidd, K. Ramsay, C. Wainwright, S. Tai, S. Bell (Brisbane, Australia)

Source: Annual Congress 2010 - Cystic fibrosis: lung disease infection and more
Session: Cystic fibrosis: lung disease infection and more
Session type: E-Communication Session
Number: 3491
Disease area: Paediatric lung diseases, Respiratory infections

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
D. Smith, T. Kidd, K. Ramsay, C. Wainwright, S. Tai, S. Bell (Brisbane, Australia). Pseudomonas aeruginosa (Pa) antibiotic resistance (AR): Comparison in adults and children with cystic fibrosis (CF). Eur Respir J 2010; 36: Suppl. 54, 3491

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Role of the specific airway resistance (sRaw) in 4-6 years fibrosis cistic patients
Source: Eur Respir J 2004; 24: Suppl. 48, 386s
Year: 2004

Relationship between nasal potential difference (NPD) and respiratory function in cystic fibrosis (CF) patients
Source: Eur Respir J 2001; 18: Suppl. 33, 125s
Year: 2001

Dual release ciprofloxacin for inhalation (DRCFI) reduces sputum pseudomonas aeruginosa (Pa) density and delays time to infective pulmonary exacerbation in non-cystic fibrosis (CF) bronchiectasis (BE)
Source: Annual Congress 2011 - Advances in antibiotic therapy of non-cystic fibrosis bronchiectasis
Year: 2011


The prevalence and characteristics of intravenous (IV) antibiotics allergy in adult patient with cystic fibrosis (CF)
Source: Annual Congress 2012 - Cystic fibrosis (adults and children): risk factors and clinical problems
Year: 2012

Serial measures of airway function in infants & preschoolers with cystic fibrosis (CF) according to pseudomonas aeruginosa (PsA) status
Source: Eur Respir J 2007; 30: Suppl. 51, 449s
Year: 2007

Monitoring small airways disease (SAD) in cystic fibrosis (CF)
Source: Annual Congress 2011 - Monitoring with lung function tests in airway diseases
Year: 2011


Effect of prior year pulmonary exacerbation (PE) frequency on response to ARD-3150 in patients with non-cystic fibrosis bronchiectasis (NCFB) chronically infected with Pseudomonas aeruginosa (PA)
Source: International Congress 2018 – Improving the quality of life of patients with bronchiectasis
Year: 2018


Late Breaking Abstract - Reduction in frequency of pulmonary exacerbations (PE) with inhaled ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB) patients is independent of Pseudomonas aeruginosa (PA) susceptibility at baseline
Source: International Congress 2017 – Update on community acquired pneumonia
Year: 2017



8.1 ancestral haplotype (AH) protects against colonization in cystic fibrosis (CF)
Source: Eur Respir J 2005; 26: Suppl. 49, 726s
Year: 2005

Macrolides in cystic fibrosis (CF); clinical experience
Source: Eur Respir J 2004; 24: Suppl. 48, 615s
Year: 2004

p.Leu206Trp mutation: Genotype-phenotype correlation in 23 paediatric / adults cystic fibrosis (CF) patients
Source: Annual Congress 2013 –Cystic fibrosis: clinical problems, genetics and microbiology in children
Year: 2013


TGFβ1 genotype in correlation to TGFβ1 induced sputum (IS) and serum in cystic fibrosis (CF)
Source: Annual Congress 2011 - Cystic fibrosis: new basic, clinical and bacteriological knowledge
Year: 2011

Ventilation inhomogeneity (VI) and spirometry in response to intravenous antibiotics (IVab) in cystic fibrosis (CF)
Source: Annual Congress 2013 –Cystic fibrosis: physiotherapy, exercise and lung function in adults and children
Year: 2013


Lung clearance index (LCI) and hyperinflation in children with cystic fibrosis (CF)
Source: Annual Congress 2012 - Cystic fibrosis (adults and children): new basic and clinical physiology research
Year: 2012


Pneumococcal antibody levels in children with cystic fibrosis (CF)
Source: Annual Congress 2010 - New aspects of cystic fibrosis
Year: 2010

Is lung function diminished by 3 months of age in infants with cystic fibrosis (CF) diagnosed by newborn screening (NBS)?
Source: Annual Congress 2010 - Functional assessment of paediatric lung disease
Year: 2010


Azithromycin (AZM) regulates glutathione-S-transferases (GST)s in cystic fibrosis (CF) airway cells
Source: Annual Congress 2008 - Cystic fibrosis: new mechanisms, monitoring and treatment tools
Year: 2008


Improving identification and treatment of children & adolescents with cystic fibrosis related diabetes (CFRD)
Source: Annual Congress 2012 - Cystic fibrosis (adults and children): risk factors and clinical problems
Year: 2012


Ventilation distribution is not influenced by structural lung disease in infants with cystic fibrosis (CF) diagnosed following newborn screening (NBS)
Source: Annual Congress 2009 - Cystic fibrosis: disease progression and novel therapies
Year: 2009

Nasal potential difference (NPD) in cystic fibrosis (CF) and non-CF patients with borderline sweat test
Source: Eur Respir J 2001; 18: Suppl. 33, 215s
Year: 2001